-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TsfNafmiB6OLO0jCSB63n3UrBNc89+OuP2Gvd2Og085FOeGQDkBGGhPwONp2GEt2 44SmaNGXb51zoVHCNkUkmg== 0001223203-08-000095.txt : 20080527 0001223203-08-000095.hdr.sgml : 20080526 20080527122940 ACCESSION NUMBER: 0001223203-08-000095 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080522 FILED AS OF DATE: 20080527 DATE AS OF CHANGE: 20080527 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENZYME CORP CENTRAL INDEX KEY: 0000732485 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061047163 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQ CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6172527500 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GERAGHTY JAMES A CENTRAL INDEX KEY: 0001239746 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14680 FILM NUMBER: 08859968 BUSINESS ADDRESS: STREET 1: C/O GTC BIOTHERAPEUTICS, INC. STREET 2: 175 CROSSING BOULEVARD CITY: FRAMINGHAM STATE: MA ZIP: 01702 BUSINESS PHONE: 5086209700 MAIL ADDRESS: STREET 1: GTC BIOTHERAPEUTICS, INC. STREET 2: 175 CROSSING BOULEVARD CITY: FRAMINGHAM STATE: MA ZIP: 01702 4 1 ger381.xml X0202 4 2008-05-22 0 0000732485 GENZYME CORP GENZ 0001239746 GERAGHTY JAMES A GENZYME CORPORATION 500 KENDALL STREET CAMBRIDGE MA 02142 0 1 0 0 Senior Vice President Genzyme NQ Stock Option (right to buy) 68.48 2008-05-22 4 A 0 15000 0 A 2008-05-22 2018-05-22 Genzyme common stock (GENZ) 15000 15000 D Genzyme Restricted Stock Units 2008-05-22 4 A 0 5000 0 A 2011-05-22 Genzyme common stock (GENZ) 5000 5000 D Options vest in 20% annual increments beginning on the original date of grant. Each restricted stock unit represents a contingent right to receive one share of Genzyme common stock. The restricted stock units vest 100% on the 3rd anniversary of the date of grant. By: Susan P. Cogswell, Attorney-in-Fact 2008-05-27 -----END PRIVACY-ENHANCED MESSAGE-----